Scheduled Maintenance
We have scheduled some maintenance on Saturday 4th of May 2024 starting from 10AM CEST and could last for 2 hours. During this maintenance we are expecting our website to be unavailable or not fully functional.
CODEXIS INC (CDXS)
US1920051067 - Common Stock
Taking everything into account, CDXS scores 3 out of 10 in our fundamental rating. CDXS was compared to 58 industry peers in the Life Sciences Tools & Services industry. While CDXS seems to be doing ok healthwise, there are quite some concerns on its profitability. CDXS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CDXS has reported negative net income.
CDXS had a negative operating cash flow in the past year.
CDXS had negative earnings in each of the past 5 years.
In the past 5 years CDXS reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -55.83%, CDXS is doing worse than 91.38% of the companies in the same industry.
With a Return On Equity value of -88.02%, CDXS is not doing good in the industry: 82.76% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.83% | ||
| ROE | -88.02% | ||
| ROIC | N/A |
ROA(3y)-25.96%
ROA(5y)-19.34%
ROE(3y)-41.39%
ROE(5y)-29.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CDXS (81.75%) is better than 96.55% of its industry peers.
In the last couple of years the Gross Margin of CDXS has remained more or less at the same level.
CDXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.71%
GM growth 5Y0.63%
2. Health
2.1 Basic Checks
CDXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDXS has more shares outstanding
The number of shares outstanding for CDXS has been increased compared to 5 years ago.
There is no outstanding debt for CDXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.58, we must say that CDXS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.58, CDXS is not doing good in the industry: 82.76% of the companies in the same industry are doing better.
CDXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.58 |
ROIC/WACCN/A
WACC12.32%
2.3 Liquidity
A Current Ratio of 2.61 indicates that CDXS has no problem at all paying its short term obligations.
CDXS has a Current ratio of 2.61. This is comparable to the rest of the industry: CDXS outperforms 50.00% of its industry peers.
CDXS has a Quick Ratio of 2.53. This indicates that CDXS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CDXS (2.53) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.61 | ||
| Quick Ratio | 2.53 |
3. Growth
3.1 Past
CDXS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -141.30%.
Looking at the last year, CDXS shows a very negative growth in Revenue. The Revenue has decreased by -49.39% in the last year.
The Revenue has been growing slightly by 2.97% on average over the past years.
EPS 1Y (TTM)-141.3%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q28.57%
Revenue 1Y (TTM)-49.39%
Revenue growth 3Y0.5%
Revenue growth 5Y2.97%
Revenue growth Q2Q-12.57%
3.2 Future
Based on estimates for the next years, CDXS will show a very strong growth in Earnings Per Share. The EPS will grow by 34.07% on average per year.
CDXS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.57% yearly.
EPS Next Y40.66%
EPS Next 2Y17.14%
EPS Next 3Y22.01%
EPS Next 5Y34.07%
Revenue Next Year-0.14%
Revenue Next 2Y-2.65%
Revenue Next 3Y8.74%
Revenue Next 5Y23.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CDXS. In the last year negative earnings were reported.
Also next year CDXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDXS's earnings are expected to grow with 22.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.14%
EPS Next 3Y22.01%
5. Dividend
5.1 Amount
CDXS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CODEXIS INC
NASDAQ:CDXS (5/3/2024, 7:00:02 PM)
After market: 3.95 +0.03 (+0.77%)3.92
+0.58 (+17.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap275.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.83% | ||
| ROE | -88.02% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.61 | ||
| Quick Ratio | 2.53 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-141.3%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y40.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-49.39%
Revenue growth 3Y0.5%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y